BlueRun Ventures | Luchen Tech Closes Nearly 100 Million RMB Series A+ Round

Luchen Tech recently completed a nearly RMB 100 million Series A+ round, led by a Fortune 500 tech giant, with participation from Greater Bay Area Fund and SingTel Innov8.

BlueRun Ventures was Luchen Tech's angel round investor.

Luchen Tech is dedicated to unleashing AI productivity, building Colossal-AI — a general-purpose deep learning system for the large model era that efficiently accelerates AI foundation model deployment. Colossal-AI has garnered over 35,000 stars on GitHub, ranking first in its niche globally. The open-source Colossal-LLaMA model surpassed 180,000 downloads on Hugging Face within three weeks. Meanwhile, Luchen's integrated hardware and cloud platform built around Colossal-AI has achieved initial success with rapid revenue growth. The company has secured multiple Fortune 500 paying customers and successfully advanced commercial AI foundation model adoption across multiple sectors worldwide.

👇 Seeking funding or partnership? Long-press the QR code below to add BlueRun's WeChat contact and connect with us directly 👇

▶ More Content ◀

Founded in Silicon Valley in 2005, BlueRun Ventures is a venture capital firm focused on early-stage startups.

The firm currently manages multiple USD and RMB dual-currency funds in China, with assets under management exceeding RMB 15 billion, making it one of the largest early-stage funds domestically. Its investment stage focuses on Pre-A and Series A rounds, covering technology, consumer, and healthcare sectors. It has invested in nearly 200 companies, including Li Auto, Waterdrop, QingCloud, Guazi.com, Qudian, Ganji.com, Energy Monster, Gaussian Robotics, Songguo Mobility, YTMicro, Machenike, CloudSaints, Anxin NetShield, and BioMap.

BlueRun Ventures has been ranked #1 on Zero2IPO's "China's Top 30 Early-Stage Investment Institutions" and ChinaVenture's "China Best Early-Stage Venture Capital Firms TOP30," and was named among Preqin's Top 10 VC fund managers globally for consistent high returns.

The firm has also received consecutive accolades from Forbes China, 36Kr, Cyzone, Caixin Media, CBNweekly, Jiemian, and other media outlets as "China's Best Early-Stage Firm of the Year," "China's Top Venture Capital Firm," "Most Entrepreneur-Friendly Early-Stage Firm of the Year," and "Most Influential Early-Stage Firm of the Year."